217 related articles for article (PubMed ID: 18953107)
41. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and Safety of Glycogen Synthase Kinase 3 Inhibitors for Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Matsunaga S; Fujishiro H; Takechi H
J Alzheimers Dis; 2019; 69(4):1031-1039. PubMed ID: 31156177
[TBL] [Abstract][Full Text] [Related]
43. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.
Leroy K; Boutajangout A; Authelet M; Woodgett JR; Anderton BH; Brion JP
Acta Neuropathol; 2002 Feb; 103(2):91-9. PubMed ID: 11810173
[TBL] [Abstract][Full Text] [Related]
44. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.
Imahori K; Uchida T
J Biochem; 1997 Feb; 121(2):179-88. PubMed ID: 9089387
[TBL] [Abstract][Full Text] [Related]
45. GSK-3 is essential in the pathogenesis of Alzheimer's disease.
Takashima A
J Alzheimers Dis; 2006; 9(3 Suppl):309-17. PubMed ID: 16914869
[TBL] [Abstract][Full Text] [Related]
46. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
47. Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link.
Zhang Y; Huang NQ; Yan F; Jin H; Zhou SY; Shi JS; Jin F
Behav Brain Res; 2018 Feb; 339():57-65. PubMed ID: 29158110
[TBL] [Abstract][Full Text] [Related]
48. Tau therapeutic strategies for the treatment of Alzheimer's disease.
Churcher I
Curr Top Med Chem; 2006; 6(6):579-95. PubMed ID: 16712493
[TBL] [Abstract][Full Text] [Related]
49. A unique type of GSK-3 inhibitor brings new opportunities to the clinic.
Licht-Murava A; Paz R; Vaks L; Avrahami L; Plotkin B; Eisenstein M; Eldar-Finkelman H
Sci Signal; 2016 Nov; 9(454):ra110. PubMed ID: 27902447
[TBL] [Abstract][Full Text] [Related]
50. The molecular bases of Alzheimer's disease and other neurodegenerative disorders.
Maccioni RB; Muñoz JP; Barbeito L
Arch Med Res; 2001; 32(5):367-81. PubMed ID: 11578751
[TBL] [Abstract][Full Text] [Related]
51. Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease.
Martinez A; Perez DI; Gil C
Curr Top Med Chem; 2013; 13(15):1808-19. PubMed ID: 23931441
[TBL] [Abstract][Full Text] [Related]
52. [Involvement of tau protein kinase in amyloid-beta-induced neurodegeneration].
Ishiguro K
Rinsho Byori; 1998 Oct; 46(10):1003-7. PubMed ID: 9816911
[TBL] [Abstract][Full Text] [Related]
53. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease.
Kazim SF; Blanchard J; Dai CL; Tung YC; LaFerla FM; Iqbal IG; Iqbal K
Neurobiol Dis; 2014 Nov; 71():110-30. PubMed ID: 25046994
[TBL] [Abstract][Full Text] [Related]
54. Isorhynchophylline treatment improves the amyloid-β-induced cognitive impairment in rats via inhibition of neuronal apoptosis and tau protein hyperphosphorylation.
Xian YF; Mao QQ; Wu JC; Su ZR; Chen JN; Lai XP; Ip SP; Lin ZX
J Alzheimers Dis; 2014; 39(2):331-46. PubMed ID: 24164737
[TBL] [Abstract][Full Text] [Related]
55. GSK3 inhibitors and disease.
Hernández F; Nido JD; Avila J; Villanueva N
Mini Rev Med Chem; 2009 Aug; 9(9):1024-9. PubMed ID: 19689399
[TBL] [Abstract][Full Text] [Related]
56. Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory.
Liu SJ; Zhang AH; Li HL; Wang Q; Deng HM; Netzer WJ; Xu H; Wang JZ
J Neurochem; 2003 Dec; 87(6):1333-44. PubMed ID: 14713290
[TBL] [Abstract][Full Text] [Related]
57. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3.
Koh SH; Noh MY; Kim SH
Brain Res; 2008 Jan; 1188():254-62. PubMed ID: 18031715
[TBL] [Abstract][Full Text] [Related]
58. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes.
Pei JJ; Braak E; Braak H; Grundke-Iqbal I; Iqbal K; Winblad B; Cowburn RF
J Neuropathol Exp Neurol; 1999 Sep; 58(9):1010-9. PubMed ID: 10499443
[TBL] [Abstract][Full Text] [Related]
59. Association between glycogen synthase kinase-3beta genetic polymorphism and late-onset Alzheimer's disease.
Mateo I; Infante J; Llorca J; Rodríguez E; Berciano J; Combarros O
Dement Geriatr Cogn Disord; 2006; 21(4):228-32. PubMed ID: 16428884
[TBL] [Abstract][Full Text] [Related]
60. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].
Liu SN; Shen ZF
Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
